JP2024534947A - シヌクレイノパチーを治療するための組成物及び方法 - Google Patents
シヌクレイノパチーを治療するための組成物及び方法 Download PDFInfo
- Publication number
- JP2024534947A JP2024534947A JP2024515041A JP2024515041A JP2024534947A JP 2024534947 A JP2024534947 A JP 2024534947A JP 2024515041 A JP2024515041 A JP 2024515041A JP 2024515041 A JP2024515041 A JP 2024515041A JP 2024534947 A JP2024534947 A JP 2024534947A
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- alpha synuclein
- pharmaceutical composition
- liquid pharmaceutical
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21197120.5 | 2021-09-16 | ||
| EP21197120 | 2021-09-16 | ||
| PCT/EP2022/075402 WO2023041524A2 (en) | 2021-09-16 | 2022-09-13 | Compositions and methods for treating synucleinopathies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024534947A true JP2024534947A (ja) | 2024-09-26 |
| JP2024534947A5 JP2024534947A5 (cg-RX-API-DMAC7.html) | 2025-09-05 |
Family
ID=78049153
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024515041A Pending JP2024534947A (ja) | 2021-09-16 | 2022-09-13 | シヌクレイノパチーを治療するための組成物及び方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (6) | US12077578B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4401770A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024534947A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240055758A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117915952A (cg-RX-API-DMAC7.html) |
| AR (1) | AR127054A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022348798A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3230055A1 (cg-RX-API-DMAC7.html) |
| CL (2) | CL2024000753A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL311344A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024002970A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023041524A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2019114679A (ru) * | 2016-11-15 | 2020-12-17 | Х. Лундбекк А/С | Средства, пути применения и способы лечения синуклеопатии |
| IL311344A (en) | 2021-09-16 | 2024-05-01 | H Lundbeck As | Preparations and methods for the treatment of synoclinopathies |
| IL326387A (en) * | 2023-09-14 | 2026-04-01 | Hoffmann La Roche | Antibody formulation |
| WO2025186235A1 (en) | 2024-03-05 | 2025-09-12 | H. Lundbeck A/S | Compositions and methods for treating multiple system atrophy (msa) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2361928T3 (en) * | 2003-05-19 | 2017-07-03 | Prothena Biosciences Ltd | Truncated fragments of alpha synuclein in Lewy body disease |
| US10513555B2 (en) * | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
| CN114717264A (zh) | 2014-11-14 | 2022-07-08 | 沃雅戈治疗公司 | 治疗肌萎缩性侧索硬化(als)的组合物和方法 |
| GB201512203D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
| WO2017176835A2 (en) * | 2016-04-06 | 2017-10-12 | Imago Pharmaceuticals, Inc. | Therapeutic antibodies for treatment of neurodegeneration |
| RU2019114679A (ru) * | 2016-11-15 | 2020-12-17 | Х. Лундбекк А/С | Средства, пути применения и способы лечения синуклеопатии |
| JOP20190227A1 (ar) * | 2017-03-31 | 2019-09-30 | Biogen Int Neuroscience Gmbh | تركيبات وطرق لعلاج اعتلالات السينوكلين |
| IL311344A (en) | 2021-09-16 | 2024-05-01 | H Lundbeck As | Preparations and methods for the treatment of synoclinopathies |
-
2022
- 2022-09-13 IL IL311344A patent/IL311344A/en unknown
- 2022-09-13 CA CA3230055A patent/CA3230055A1/en active Pending
- 2022-09-13 JP JP2024515041A patent/JP2024534947A/ja active Pending
- 2022-09-13 CN CN202280060631.5A patent/CN117915952A/zh active Pending
- 2022-09-13 WO PCT/EP2022/075402 patent/WO2023041524A2/en not_active Ceased
- 2022-09-13 MX MX2024002970A patent/MX2024002970A/es unknown
- 2022-09-13 KR KR1020247008828A patent/KR20240055758A/ko active Pending
- 2022-09-13 EP EP22789489.6A patent/EP4401770A2/en active Pending
- 2022-09-13 AU AU2022348798A patent/AU2022348798A1/en active Pending
- 2022-09-13 AR ARP220102483A patent/AR127054A1/es unknown
-
2023
- 2023-06-26 US US18/341,437 patent/US12077578B2/en active Active
-
2024
- 2024-03-13 CL CL2024000753A patent/CL2024000753A1/es unknown
- 2024-07-15 US US18/773,301 patent/US20250084156A1/en active Pending
- 2024-07-16 US US18/774,629 patent/US12351624B2/en active Active
- 2024-07-16 US US18/774,646 patent/US12358975B2/en active Active
- 2024-07-16 US US18/774,608 patent/US12358974B2/en active Active
- 2024-12-03 CL CL2024003713A patent/CL2024003713A1/es unknown
-
2025
- 2025-12-22 US US19/429,170 patent/US20260217807A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023041524A3 (en) | 2023-05-11 |
| US12351624B2 (en) | 2025-07-08 |
| US12358975B2 (en) | 2025-07-15 |
| US20240400661A1 (en) | 2024-12-05 |
| EP4401770A2 (en) | 2024-07-24 |
| CA3230055A1 (en) | 2023-03-23 |
| CL2024003713A1 (es) | 2025-04-21 |
| IL311344A (en) | 2024-05-01 |
| CN117915952A (zh) | 2024-04-19 |
| US20240400660A1 (en) | 2024-12-05 |
| AU2022348798A1 (en) | 2024-03-14 |
| US20240400662A1 (en) | 2024-12-05 |
| US12358974B2 (en) | 2025-07-15 |
| CL2024000753A1 (es) | 2024-09-23 |
| US20240025979A1 (en) | 2024-01-25 |
| US20250084156A1 (en) | 2025-03-13 |
| WO2023041524A2 (en) | 2023-03-23 |
| KR20240055758A (ko) | 2024-04-29 |
| US12077578B2 (en) | 2024-09-03 |
| MX2024002970A (es) | 2024-03-27 |
| US20260217807A1 (en) | 2026-07-30 |
| AR127054A1 (es) | 2023-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12077578B2 (en) | Compositions and methods for treating synucleinopathies | |
| JP7277649B2 (ja) | 高濃度抗c5抗体製剤 | |
| US20240058418A1 (en) | High Concentration VEGF Receptor Fusion Protein Containing Formulations | |
| US20230071973A1 (en) | Pharmaceutical formulations and dosage regimens for factor xi/xia antibodies | |
| WO2020173431A2 (zh) | 包含抗cd47抗体的制剂及其制备方法和用途 | |
| US20250282855A1 (en) | Compositions and methods for treating multiple system atrophy (msa) | |
| HK40106296A (en) | High concentration vegf receptor fusion protein containing formulations | |
| HK40106296B (en) | High concentration vegf receptor fusion protein containing formulations | |
| JP2024521390A (ja) | 抗IgE抗体を含有する医薬製剤 | |
| EA046718B1 (ru) | Составы, содержащие слитый белок рецептора фрэс в высокой концентрации |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250828 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250828 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20260702 |